DEMONSTRATION BASED ON SYNTHETIC DATA

Even Top Research Has Temporal Blind Spots

TRS Analysis of 100 Highly-Cited Papers (2022-2025)

Important Notice Regarding TRS Demonstration: scoring examples and validation analyses presented on this site are currently hypothetical, designed to illustrate the framework’s methodology and potential applications. Scientari LLC is actively developing a comprehensive TRS Agent that will enable systematic, reproducible scoring of research protocols and published studies. Once released, we will include analyses of peer-reviewed papers using our validated TRS Agent, along with complete methodological documentation, inter-rater reliability metrics, and a full list of scored papers with transparent scoring rationales. A hypothetical analysis of papers from leading journals might result in an average TRS score: 26.6/40. The following conceptual section is to demonstrate the study flaws we might identify and how to fix them.

View Key Findings Jump to Papers

100

Papers Analyzed

2022-2025

26.6/40

Average TRS Score

Good, not excellent

63%

Miss Early Timepoints

Days 1-7 (T1-T2)

$500-5K

Cost to Improve TRS

6-8 point gain

Key Findings

Analysis of 100 highly-cited papers from top journals reveals systematic temporal gaps

🚨 Missing T1-T2 Early Dynamics

63%

of studies skip Day 1-7 measurements—the critical window for immune activation, drug PK/PD, and early response signals.

Impact: Missing non-responders until Week 8-12 when they could be identified by Day 7. Wastes $3-5M per trial.

⚠️ Sparse T3 Tissue Monitoring

54%

measure only baseline + endpoint, missing weeks-scale tissue remodeling, immune infiltration, and resistance mechanisms.

Impact: Can't distinguish early responders from late failures. Spatial transcriptomics underutilized.

⏰ Limited T5 Long-term Follow-up

80%

stop at 12-24 months, missing chronic toxicities, durability assessment, and late relapses that define real-world outcomes.

Impact: Regulatory submissions lack durability data. Patient safety signals missed.

✅ The Fix Is Affordable

$500-5K

per patient to add early blood draws, on-treatment biopsies, or extended follow-up. Increases TRS by 6-8 points.

Impact: Better patient stratification, earlier go/no-go decisions, regulatory-grade durability data.

Hypothetical TRS Analysis: 100 Papers

Full analysis and actionable recommendations for each paper. Click paper titles to view on PubMed.

#	Paper Title	Journal (Year)	Category	TRS	Analysis & Recommendations

💎 The TemporalBio Opportunity

"Even the best research—published in Nature, Cell, Science, and top medical journals—scores only 26.6/40 on temporal readiness. These aren't bad studies; they're excellent science with temporal blind spots."

The Problem

63% miss early timepoints (Day 1-7)
54% skip intermediate monitoring (weeks)
80% lack long-term follow-up (2+ years)
Billions wasted on late failure detection

The Solution

Add early monitoring: $500-1,000/patient
On-treatment biopsies: $2,000-5,000/patient
Extended follow-up: $500-1,000/patient/year
6-8 point TRS improvement → millions saved

The Impact

Identify non-responders by Week 6 vs Month 12
$3-5M savings per Phase 2 trial
Patent-ready biomarker signatures
Higher clinical trial success rates

Analyze Your Study with TRS Agent →